RGLS - Regulus Therapeutics Inc Stock Price, Fair Value and News

$8.16

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RGLS Price Action

Last 7 days

-2.8%

Last 30 days

-0.5%

Last 90 days

475.2%

Trailing 12 Months

212.7%

RGLS RSI Chart

RGLS Valuation

Market Cap

565.0M

Price/Earnings (Trailing)

-11.89

Price/Sales (Trailing)

130.64

EV/EBITDA

-10.93

Price/Free Cashflow

-12.94

RGLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RGLS Fundamentals

RGLS Revenue

Revenue (TTM)

4.3M

RGLS Earnings

Earnings (TTM)

-47.5M

Earnings Growth (Yr)

-13.76%

Earnings Growth (Qtr)

24.68%

RGLS Profitability

EBT Margin

-1098.90%

Return on Equity

-68.85%

Return on Assets

-63.51%

Free Cashflow Yield

-7.73%

RGLS Investor Care

Shares Dilution (1Y)

5.76%

Diluted EPS (TTM)

-0.7

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	2.5M	3.2M	3.8M
2023	976.0K	1.4M	1.7M	1.7M
2022	0	0	1.1M	562.0K
2021	0	10.4M	10.8M	5.9M
2020	7.6M	8.4M	9.2M	10.0M
2019	2.8M	4.1M	5.5M	6.8M
2018	72.0K	72.0K	72.0K	1.4M
2017	913.5K	633.0K	352.5K	72.0K
2016	15.9M	11.0M	6.1M	1.2M
2015	10.2M	13.3M	14.1M	20.8M
2014	18.0M	13.9M	8.9M	7.7M
2013	12.6M	14.0M	17.4M	19.6M
2012	13.8M	13.8M	12.8M	12.7M
2011	9.9M	11.2M	12.5M	13.8M
2010	0	0	0	8.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

CEO	Mr. Joseph P. Hagan M.B.A.
WEBSITE	regulusrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30

Regulus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Regulus Therapeutics Inc? What does RGLS stand for in stocks?

RGLS is the stock ticker symbol of Regulus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regulus Therapeutics Inc (RGLS)?

As of Thu Jun 26 2025, market cap of Regulus Therapeutics Inc is 564.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGLS stock?

You can check RGLS's fair value in chart for subscribers.

Is Regulus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RGLS is over valued or under valued. Whether Regulus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Regulus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGLS.

What is Regulus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 26 2025, RGLS's PE ratio (Price to Earnings) is -11.89 and Price to Sales (PS) ratio is 130.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGLS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regulus Therapeutics Inc's stock?

In the past 10 years, Regulus Therapeutics Inc has provided -0.399 (multiply by 100 for percentage) rate of return.